体育用品的研发与市场销售..docx

Results of Operations (amounts in thousands unless otherwise noted)经营业绩（单位：除非另有说明） Revenues:收入 Our sources of revenue during the years ended December 31, 2011, 2010 and 2009, included our License Agreement with Salix,Transition Agreement with Wyeth, our License Agreement with Ono, our research grants from the NIH and, to a small extent, our sale ofresearch reagents.2011年12月31日止年度，2010年和2009年，我们的收入来源，包括我们与柳许可协议，和惠氏的过渡协议，我们与小野的许可协议，我们的研究资助，由美国国立卫生研究院，并在小范围内，我们销售研究试剂。 Collaboration revenue:合作收入 Salix Collaboration. During the year ended December 31, 2011, we recognized $75,091 of revenue from Salix, which includes$59,634 from the $60,000 upfront cash payment under the License Agreement, $225 in respect of Salix ex-U.S. sublicensee revenue and$15,232 as reimbursement of our expenses, including $2,172 of manufacturing supplies, in accordance with the License Agreement. As ofDecember 31, 2011, $204 and $162 are recorded in deferred revenue – current and long-term, respectively. Wyeth Collaboration. During the years ended December 31, 2011 and 2010, we recognized $1,630 and $1,383, respectively, ofrevenue from Wyeth, as reimbursement of our expenses under the 2009 Transition Agreement. During the years ended December 31, 2010 and 2009, we recognized $1,383 and $29,298, respectively, of revenue from Wyeth,consisting of (i) $0 and $14,562, respectively, of the $60,000 upfront payment we received upon entering into our 2005 collaboration, (ii) $0and $4,736, respectively, as reimbursement of our development expenses, and (iii) $1,383 and $10,000, respectively, as reimbursement of ourexpenses under the 2009 Transition Agreement./essaygeshi/ Ono Collaboration. During the years ended December 31, 2011 and 2010, we recognized $43 and $30, respectively, ofreimbursement revenue for activities requested by Ono.我们认识到，二零一一年及二零一零年十二月三十一日止期间，$43和$30，分别，小野合作补偿收入所要求的小野的活动。 During the years ended December 31, 2010 and 2009, we recognized $30 and $53, respectively, of reimbursement